CytomX Appoints Alison Hannah Senior VP and Chief Medical Officer

Alison Hannah has joined CytomX (NASDAQ: [[ticker:CTMX]]) as senior vice president and chief medical officer. Hannah was most recently a consultant to pharmaceutical and biotechnology companies. Her experience also includes positions at Sugen and Quintiles. South San Francisco-based CytomX is developing a type of cancer treatment it calls a “Probody drug.” The company’s pipeline includes wholly owned compounds, as well as programs in development under partnerships with Bristol-Myers Squibb (NYSE: [[ticker:BMY]]), AbbVie (NYSE: [[ticker:ABBV]]), and Amgen (NASDAQ: [[ticker:AMGN]]).

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan